366 results
Page 3 of 19
8-K
EX-1.1
vajypl
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.2
nbe5rou5skkb6r b8
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-5.1
ht3n39qvxlp
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-4.1
rz2f69fvytf
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
424B5
pj3yihpjf
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
03h6g4c k5
30 Nov 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
ux96 ssdw
30 Nov 21
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-4.1
lqkbor
12 Aug 21
Entry into a Material Definitive Agreement
10:14am
8-K
EX-10.1
p5cf7y62z
12 Aug 21
Entry into a Material Definitive Agreement
10:14am
8-K
EX-5.1
a15 b4vgyx6cj
12 Aug 21
Entry into a Material Definitive Agreement
10:14am
424B5
cvhqf mxnwbx
12 Aug 21
Prospectus supplement for primary offering
10:11am
S-8
EX-23.1
jpelioiexv7uux7wa8
9 Aug 21
Registration of securities for employees
4:10pm
S-8
EX-23.1
4dv uh5z1
9 Aug 21
Registration of securities for employees
4:10pm
8-K
omrhakcxypqzu6
17 Jun 21
Departure of Directors or Certain Officers
4:13pm
DEFA14A
i8jf9os4rmx9
28 Apr 21
Additional proxy soliciting materials
4:06pm
S-8
EX-23.1
aqetg8wbcqecifameay
2 Mar 21
Registration of securities for employees
12:00am